

A Video from the NIH Director's Wednesday Afternoon Lecture Series

GENES, LIFESTYLE, AND RISK FOR HEART ATTACK

Sekar Kathiresan, M.D. , Co-founder and CEO of Verve Therapeutics.

Verve is developing therapies to safely edit the adult genome and confer lifelong protection from cardiovascular disease.

Coronary artery disease is the leading global cause of mortality. Long recognized to be heritable, recent advances have started to unravel the genetic architecture of the disease. Genetic testing could enable precision-medicine approaches by identifying subgroups of patients who are at increased risk of coronary artery disease or have a specific driving pathophysiology that would make a therapeutic or preventive approach most useful.

Lunch will be served. Brief discussion to follow.

WHEN: February 10
12:00 — 1:00 p.m.

WHERE: Bondurant G100

RSVP: February 6
to kriste.kuczynski@unc.edu

Sponsored by the Center for Genomics and Society and the UNC Program for Precision Medicine in Healthcare.